DOCKET NO.: ORT-1461 Application No.: 09/921,512

Office Action Dated: March 20, 2003

Listing of Claims:

- Claim 1 (Original): A method for inhibiting replication of KSHV comprising administration of a compound that inhibits c-Kit signalling pathway.
- Claim 2 (Original): A method for the treatment of Kaposi sarcoma comprising administration of a compound that inhibits c-Kit signalling pathway.
- Claim 3 (Original): A method for inhibiting replication of KSHV comprising administration of a compound that inhibits type I sigma receptor signalling pathway.
- Claim 4 (Original): A method for the treatment of Kaposi sarcoma comprising administration of a compound that inhibits type I sigma receptor signalling pathway.
- Claim 5 (Original): A gene expression profile specific for the lytic phase of KSHV replication comprising at least one gene selected from a group consisting of the genes listed in Table 2.
- Claim 6 (Original): A gene expression profile specific for the latent phase of KSHV replication comprising at least one gene selected from a group consisting of the genes listed in Table 2.
- Claim 7 (Original): A microarray comprising nucleic acid encoding a probe to hybridize with one or more of the genes selected from a group consisting of the genes listed in Table 2.

PATENT

DOCKET NO.: ORT-1461 Application No.: 09/921,512

Office Action Dated: March 20, 2003

Claim 8 (Original): A method for diagnosing KSHV or the stage of KSHV replication comprising:

- a) obtaining a sample of cells suspected of being infected with KSHV;
- b) extracting RNA from the cells;
- c) contacting the RNA with a microarray comprising nucleic acid encoding a
 probe specific for one or more of the genes selected from a group consisting
 of the genes listed in Table 2; and
- d) determining the gene expression profile of the sample of cells and comparing it with the gene expression profile of KSHV infected cells.

Claim 9 (Original): A method for identifying modulators of KSHV replication, comprising:

- a) selecting a gene product from a group of genes consisting of the genes listed in Table 2;
- combining a test compound with the gene product encoded by the gene to determine whether the test compound inhibits or activates the gene product; and
- c) combining the test compound with KSHV infected cells to determine whether the test compound inhibits or activates replication of the KSHV.
- Claim 10 (Original): A method for inhibiting replication of KSHV comprising administration of a compound that inhibits c-Kit and administration of a compound that modulates KSHV replication by a mechanism other than inhibition of c-Kit.
- Claim 11 (Original): The method of claim 10, wherein said compound that modulates KSHV replication by a mechanism other than inhibition of c-Kit is selected from a group consisting of daunorubicin, doxorubicin, interferon alpha, retinoids, and taxol.
- Claim 12 (Original): A method for the treatment of Kaposi sarcoma comprising administration of a compound that inhibits c-Kit and administration of a

PATENT

DOCKET NO.: ORT-1461 Application No.: 09/921,512

Office Action Dated: March 20, 2003

compound that modulates Kaposi sarcoma by a mechanism other than inhibition of c-Kit.

- Claim 13 (Original): The method of claim 12, wherein said compound that modulates KSHV replication by a mechanism other than inhibition of c-Kit is selected from a group consisting of daunorubicin, doxorubicin, interferon alpha, retinoids, and taxol.
- Claim 14 (Original): A method for inhibiting replication of KSHV comprising administration of a compound that inhibits type I sigma receptor and administration of a compound that modulates KSHV replication by a mechanism other than inhibition of type I sigma receptor.
- Claim 15 (Original): The method of claim 14, wherein said compound that modulates KSHV replication by a mechanism other than inhibition of type I sigma receptor is selected from a group consisting of daunorubicin, doxorubicin, interferon alpha, retinoids, and taxol.
- Claim 16 (Original): A method for the treatment of Kaposi sarcoma comprising administration of a compound that inhibits type I sigma receptor and administration of a compound that modulates Kaposi sarcoma by a mechanism other than inhibition of type I sigma receptor.
- Claim 17 (Original): The method of claim 16, wherein said compound that modulates

 Kaposi sarcoma by a mechanism other than inhibition of type I sigma receptor is
 selected from a group consisting of daunorubicin, doxorubicin, interferon alpha,
 retinoids, and taxol.
- Claim 18 (Original): A method of doing business comprising the steps of:
 - a) determining the level of RNA expression for an RNA sample, wherein said RNA sample;

PATENT

DOCKET NO.: ORT-1461 Application No.: 09/921,512

Office Action Dated: March 20, 2003

- b) is amplified and fluorescently labeled, hybridized to a microarray containing a plurality of nucleic acid sequences representing a gene expression profile, and said microarray is scanned for fluorescence;
- c) normalizing said expression level using an algorithm; and
- d) scoring said RNA sample against a gene expression profile database.
- Claim 19 (Original): The method of claim 18, wherein said RNA sample is obtained from a patient.
- Claim 20 (Original): The method of claim 19, wherein said RNA sample is isolated from a patient sample selected from the group consisting of blood, amniotic fluid, plasma, semen, bone marrow, and tissue biopsy.
- Claim 21 (Original): The method of claim 18, wherein said microarray is a DNA microarray.
- Claim 22 (Original): The method of claim 18, wherein said database is available via a web-browser interface.
- Claim 23 (Original): The method of claim 18, wherein said web-browsér provides gene sequence analysis tools.
- Claim 24 (Original): The method of claim 18, wherein a user pays a fee for access to said database.